leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 21:14:13 - browse：4

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： FDA approves first treatment for ultra

knowledge

WSS

Anthos stroke drug appears safer than common blood thinner

As Maui death toll rises, number of missing remains unclear

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Beware the threat of staffing cuts at the CDC

Liz Cheney makes 1st public comment since Trump's election interference indictments

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

focus

leisure time

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The pain doctors face in trying to build their families

Novavax promises a turnaround & Lilly roils the obesity market

World's first CRISPR

Medical records are filled with copy

Does good food count as health care? Study aims to find out

State Dept. review finds Biden bears some blame for Afghanistan failures

Cancer drug shortages' outsize impact on ovarian cancer patients

hotspot

Morphosys mixed study results for blood cancer drug

As Maui death toll rises, number of missing remains unclear

Anthos stroke drug appears safer than common blood thinner

Congress must give Medicare recipients genetic counseling access

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Ransomware attacks on hospitals: Study outlines patient impact

knowledge

knowledge

explore

entertainment